# US 2013/0274248 A1 · Compound Having Activity Of Blocking NMDA Receptor Channel, and Pharmaceutical Agent Using The Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274248 A1
- Document ID: US20130274248A1
- Status: Published application
- Kind: A1
- Application number: 13/906,424
- Filed: 2013-05-31
- Published: 2013-10-17
- Earliest claimed: 2006-04-28
- Assignees: National University Corporation Chiba University
- Applicants: National University Corporation Chiba University
- Inventors: Kazuei Igarashi; Hiromitsu Takayama
- Web page: https://patentgrep.com/patent/US20130274248A1

## CPC

- C07D 223/26: having a double bond between positions 10 and 11
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 235/84: with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 209/86: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- C07D 223/28: having a single bond between positions 10 and 11
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

[PROBLEMS] To provide a novel compound having NMDA receptor channel blocking activity, and also a pharmaceutical agent comprising the compound. [MEANS FOR SOLVING PROBLEMS] A pharmaceutical agent for the treatment or prevention of a disease caused by overexcitation of an NMDA receptor, which comprises a compound having NMDA receptor channel blocking activity and represented by the formula (1), a salt thereof, or a hydrate of the compound or the salt.

## Claims

### Claim 1

A pharmaceutical agent comprising a compound represented by the following formula (1), a salt thereof, or a hydrate of the compound or the salt,
wherein the B-ring condensed to the A-ring and the C-ring is quinone, benzene, pyrrole, pyridine, 1,4-dihydropyridine, azepine, 4,5-dihydroazepine or 1,4-thiazine, R1-R5 are each independently formyl, acyl, hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, aryl or carboxamido, and at least either of R1 or R2 is a carboxamide group having a polyamine structure containing three or more amino groups, wherein an amino group of any carboxamido group is excluded, and R1-R5 are identical or different, and a pharmaceutically acceptable carrier.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The pharmaceutical agent according to claim 1, comprising a compound represented by the following formula (4), a salt thereof, or a hydrate of the compound or the salt,

### Claim at position 4

5-6. (canceled)

### Claim 7

A compound represented by the following formula (1), or a pharmaceutically acceptable salt thereof,
where, wherein the B-ring condensed to the A-ring and the C-ring is quinone, benzene, pyrrole, pyridine, 1,4-dihydropyridine, azepine, 4,5-dihydroazepine or 1,4-thiazine, R1-R5 are each independently formyl, acyl, hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, aryl or carboxamido, and at least either of R1 or R2 is a carboxamide group having a polyamine structure containing three or more amino groups, wherein an amino group of any carboxamido group is excluded, and R1-R5 are identical or different.

### Claim 8 (depends on 7)

The compound according to claim 7, which is represented by the following formula (2),

### Claim 9 (depends on 7)

The compound according to claim 7, which is represented by the following formula (3),

### Claim 10 (depends on 7)

The compound according to claim 7, which is represented by the following formula (4),

### Claim 11

(canceled)

### Claim 12

A pharmaceutical agent comprising a compound represented by the following formula (1), a salt thereof, or a hydrate of the compound or the salt,
wherein the B-ring condensed to the A-ring and the C-ring is quinone, benzene, pyrrole, pyridine, 1,4-dihydropyridine, azepine, 4,5-dihydroazepine or 1,4-thiazine, R1-R5 are each independently formyl, acyl, hydrogen, alkyl, alkoxy, halogen, hydroxy, amino, aryl or carboxamido, and at least either of R1 or R2 consists of a carboxamide group consisting of a polyamine structure containing three or more amino groups, wherein an amino group of any carboxamido group is excluded, and R1-R5 are identical or different.
